Consistent with previous studies, the vascular remodeling induced by anti-VEGF therapy led to modest reductions in tumor burden but simultaneously created a more hypoxic TME, which is known to promote tumor cell invasion into adjacent brain tissue [282]. The gene discussed is VEGFA; the disease is neoplasm.